AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Recorded on 11/08/24
TD Cowen analyst Steve Scala speaks with former Pfizer R&D Chief John LaMattina to discuss views of the status and outlook for R&D in biopharma industry. New technologies and deeper understanding of biology provide opportunities, but price pressures and some M&A can stifle creativity. We discussed optimal R&D portfolio construction and concluded with observations on where Pfizer R&D stands today.
https://go.td.com/PodcastDisclosure